Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma CorpfiledCriticalHyal Pharma Corp
Priority to ARP960104868ApriorityCriticalpatent/AR004227A1/en
Publication of AR004227A1publicationCriticalpatent/AR004227A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Una composición farmacéutica estéril porque comprende un agente de terapia genética asociado o unido con ácido hialurónico o una salderivada del mismo aceptable para uso farmacéutico, junto con un excipiente aceptable para uso farmacéutico.A sterile pharmaceutical composition in that it comprises a gene therapy agent associated or bound with hyaluronic acid or a derivative thereof acceptable for pharmaceutical use, together with an excipient acceptable for pharmaceutical use.
ARP960104868A1996-10-231996-10-23
USE OF HYALURONAN IN GENETIC THERAPY.
AR004227A1
(en)
2-AMINO-6-METHYL-7-ACETYL-TETRALINE AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND / OR AUTOIMAL NATURE PATOLOGIES